Bayer develops 'vaginal atrophy' drug
German pharmaceutical giant Bayer is developing a kind of female Viagra in the form of a new treatment for post-menopausal women experiencing vaginal atrophy that can lead to sexual dysfunction.
The firm signed a deal Tuesday with Quebec's EndoCeutics to develop the treatment, provisionally named Vaginorm, which will boost the steroid DHEA in women's bodies.
DHEA levels naturally drop as people age. For women, that can mean vaginal tissues change and become drier, which can lead to discomfort or even pain during sex.
The deal covers the Phase III clinical development, and the marketing, of the new drug.
With the baby boomer generation nearing retirement age, pharmaceutical companies are keen to find a treatment for sexual dysfunction in older women to match the success of Viagra and other drugs for men.
EndoCeutics said it hoped to improve the quality of life of some 360 million women worldwide aged 50 or older who it said have vaginal atrophy or dryness.
AFP/dw
Comments
See Also
The firm signed a deal Tuesday with Quebec's EndoCeutics to develop the treatment, provisionally named Vaginorm, which will boost the steroid DHEA in women's bodies.
DHEA levels naturally drop as people age. For women, that can mean vaginal tissues change and become drier, which can lead to discomfort or even pain during sex.
The deal covers the Phase III clinical development, and the marketing, of the new drug.
With the baby boomer generation nearing retirement age, pharmaceutical companies are keen to find a treatment for sexual dysfunction in older women to match the success of Viagra and other drugs for men.
EndoCeutics said it hoped to improve the quality of life of some 360 million women worldwide aged 50 or older who it said have vaginal atrophy or dryness.
AFP/dw
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.